By BY SHERYL GAY STOLBERG, CHRIS HAMBY AND REBECCA R. RUIZ U.S. https://ift.tt/3wddRXl Emergent BioSolutions faces scrutiny in Congress for ruining Covid-19 vaccines and securing lucrative federal contracts. Executives will appear before some lawmakers who benefited from the company’s spending. New York Times United States Politics and Government, Government Contracts and Procurement, Campaign Finance, Coronavirus (2019-nCoV), Elections, House of Representatives, Vaccination and Immunization, Political Action Committees, Drugs (Pharmaceuticals), Lobbying and Lobbyists, Factories and Manufacturing May 18, 2021 at 11:53PM